title: Current perspectives in percutaneous atrial septal defect closure devices.
abstract: In the last decade, percutaneous atrial septal defect (ASD) closure has become the treatment of choice in most clinical presentations of ASD. Percutaneous ASD closure has established procedural safety through operator experience and improved device structure and deliverability. There have also been advances in diagnostic capabilities. Devices have evolved from large bulky meshes to repositionable, minimal residual mesh content that easily endothelializes and conforms well to surrounding structures. Biodegradable technology has been introduced and will be closely watched as a future option. The evolution of ASD closure device usage in the last four decades incorporates development that minimizes a wide range of serious side effects that have been reported over the years. Complications reported in the literature include thrombus formation, air embolization, device embolization, erosions, residual shunts, and nickel hypersensitivity. Modern devices have intermediate to long term data with outcomes that have been favorable. Devices are available in multiple sizes with improved delivery mechanisms to recapture, reposition, and safely close simple and complex ASDs amenable to percutaneous closure. In this review, commonly used devices and deployment procedures are discussed together with a look at devices that show promise for the future.
authors.affiliation: Department of Cardiology, The Epworth Hospital, Melbourne, VIC, Australia ; Division of Interventional Cardiology, The Alfred Hospital, Melbourne, VIC, Australia ; Department of Clinical Science, Charles Sturt University Albury Campus, NSW, Australia ; Heart Foundation, Griffith University, QLD, Australia.
authors.forename: N
authors.initials: N
authors.lastname: Bissessor
keywords: ASD; Amplatzer; Biostar; Figulla; Gore Helex; congenital